A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

• Progression free survival between the first dose and the earliest date of disease progression or death due to any cause. [ Time Frame: Approximately 2 years ] [ Designated as safety issue: No ]
• Duration of response for the subset of subjects with confirmed complete response (CR) or partial response (PR) from first documented evidence of CR or PR until time of first documented disease progression or death due to any cause. [ Time Frame: Approximately 2 years ] [ Designated as safety issue: No ]
• Overall survival from first dose until death due to any cause. [ Time Frame: Approximately 2 years ] [ Designated as safety issue: No ]
• Overall response rate in patients with V600K mutant melanoma. [ Time Frame: Approximately 2 years ] [ Designated as safety issue: No ]

• Progression free survival between the first dose and the earliest date of disease progression or death due to any cause. [ Time Frame: Approximately 2 years ] [ Designated as safety issue: No ]
• Duration of response for the subset of subjects with confirmed complete response (CR) or partial response (PR) from first documented evidence of CR or PR until time of first documented disease progression or death due to any cause. [ Time Frame: Approximately 2 years ] [ Designated as safety issue: No ]
• Overall survival from first dose until death due to any cause. [ Time Frame: Approximately 1-2 years. ] [ Designated as safety issue: No ]

BRF113710 is a Phase II, single-arm, open-label study to assess the efficacy, safety, and tolerability of GSK2118436 administered twice daily as a single agent in subjects with BRAF mutant metastatic melanoma. Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.

Inclusion Criteria:

• Must be at least 18 years of age
• Must have histologically confirmed cutaneous metastatic melanoma (Stage IV) that is BRAF mutation-positive (V600 E/K) as determined via central testing with a BRAF mutation assay.
• Is treatment naive or has received prior treatment for metastatic melanoma.
• Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
• Women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study treatment.
• Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication.
• Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication.
• Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
• Adequate organ function.

Exclusion Criteria:

• Previous treatment with a BRAF or MEK inhibitor.
• Cancer therapy (chemotherapy with delayed toxicity, radiation therapy, immunotherapy, biologic therapy, or major surgery) within the last 3 weeks; chemotherapy regimens without delayed toxicity within the last 2 weeks; or use of any investigational anti-cancer or other drug within 28 days or 5 half-lives, whichever is longer, preceding the first dose of GSK2118436.
• A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.
• History or evidence of brain metastases on MRI or head CT if MRI is not able to be performed.
• History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
• Certain cardiac abnormalities.